# BioCardia, Inc.: Form 10-Q for the period ended Mar 31, 2012

- Company: [BioCardia, Inc.](/companies/bcda.md) (CIK 925741)
- Form: 10-Q
- Filed: 2012-05-15
- Accepted by EDGAR: May 15, 2012, 09:55 ET
- Period: 2012-03-31
- Accession: 0001136261-12-000295
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/925741/000113626112000295/form10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/925741/000113626112000295/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-01-01 to 2012-03-31 | $11.0k | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2012-01-01 to 2012-03-31 | $0 | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2012-01-01 to 2012-03-31 | $11.0k | us-gaap:GrossProfit |
| Operating income | 3 months, 2012-01-01 to 2012-03-31 | −$58.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2012-01-01 to 2012-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-01-01 to 2012-03-31 | −$55.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2012-01-01 to 2012-03-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months, 2012-01-01 to 2012-03-31 | 230,293,141 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2012-01-01 to 2012-03-31 | −$26.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2012-01-01 to 2012-03-31 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2012-03-31 | $12.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Total assets | at 2012-03-31 | $13.6m | us-gaap:Assets |
| Total liabilities | at 2012-03-31 | $711.0k | us-gaap:Liabilities |
| Shareholders' equity | at 2012-03-31 | $12.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 12,788 characters.

The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

As used in this "Management's Discussion and Analysis of Financial Condition and Results of Operation," except where the context otherwise requires, the term "we," "us," "our" or "Tiger X" refers to the business of Tiger X Medical, Inc.

***The following discussion should be read together with the information contained in the unaudited condensed consolidated financial statements and related notes included in Item 1, "Financial Statements," in this Form 10-Q. All dollar amounts are in thousands unless otherwise specified.***

Overview

Tiger X Medical, Inc. ("Tiger X" or the "Company"), formerly known as Cardo Medical, Inc., previously operated as an orthopedic medical device company specializing in designing, developing and marketing high performance reconstructive joint devices and spinal surgical devices. As discussed below, in January 2011 we entered into an asset purchase agreement to sell substantially all of our assets in the Reconstructive Division to Arthrex. We completed the sale of the Reconstructive Division assets during the second quarter of 2011. Additionally, we completed the sale of substantially all of the assets in the Spine Division in April 2011. Our continuing operations include the collection and management of our royalty income earned in connection with the Asset Purchase Agreement with Arthrex. The Company will also be evaluating future investment opportunities and uses for its cash.

We are headquartered in Los Angeles, California. Our common stock is quoted on the National Association of Securities Dealers, Inc.'s, Over-the-Counter Bulletin Board, or the OTC Bulletin Board with a trading symbol of CDOM.OB.

### Critical Accounting Policies

### Use of Estimates

Financial statements prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among other things, management makes estimates relating to allowances for doubtful accounts, share-based payments, and deferred income tax assets. Given the short operating history of Tiger X, actual results could differ from those estimates.

### Discontinued Operations

On October 7, 2010, the Company's management and Board of Directors decided to put substantially all of its assets up for sale. The assets determined to be held for sale were inventories, intellectual properties, and property and equipment of its reconstructive products line (the "Reconstructive Division") and spine products line (the "Spine Division"). The Company decided to put the assets of its Reconstructive and Spine Divisions up for sale primarily because it did not have sufficient working capital, and was not able to procure such financial resources through equity or debt financing, in order to fully execute a profitable sales strategy.

On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex, Inc. ("Arthrex") (the agreement being the "Arthrex Asset Purchase Agreement"), pursuant to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date. The Company completed the sale of the Reconstructive Division on June 10, 2011. The total cash consideration received by the Company from Arthrex amounted to $14,586,000, which was comprised of $9,960,000 plus inventory with a value of $2,908,000 and property and equipment with a value of $1,718,000, subject to future adjustments to the value of the inventory and property and equipment and other unasserted claims over a twelve month period. During the three months ended March 31, 2012, the Company received total royalty payments of $11,000 from Arthrex and reflected this payment as revenue on the accompanying consolidated statements of operations.

On April 4, 2011, the Company entered into and closed an Asset Purchase Agreement with Altus Partners, LLC, a Delaware limited liability company ("Altus"), pursuant to which the Company sold substantially all of the assets of the Spine Division in exchange for cash consideration of $3,000,000 (the "Altus Asset Purchase Agreement"). Pursuant to the terms of the Altus Asset Purchase Agreement, $2,700,000 of the purchase price was paid at the closing and $300,000 was deposited into escrow with an escrow agent for a period of 90 days from the closing date (assuming there are no disputes) to be used for any adjustments to the closing value of the Company's inventory and property and equipment.

Pursuant to the sales transactions with Arthrex and Altus, the total aggregate amount remaining in escrow accounts was $900,000, which is reflected as restricted cash on the accompanying condensed consolidated balance sheet as of March 31, 2012 and December 31, 2011.

Total sales associated with the discontinued Reconstructive and Spine Divisions reported as discontinued operations for the three months ended March 31, 2012 and 2011, were $0 and $547,000, respectively. The total pretax loss associated with the discontinued Reconstructive and Spine Divisions, including the discontinued corporate support for those activities, reported as discontinued operations for the three months ended March 31, 2012 and 2011, were $0 and $196,000, respectively. The continuing operations reflected are expenses associated with business insurance, legal and accounting fees that the Company will continue to incur.

### Revenue Recognition

The Company's revenue consists of royalty revenue from the Arthrex Asset Purchase Agreement, which is recognized as the amount becomes known and collectability is reasonably assured.

### Recent Accounting Pronouncements

There are no recently issued accounting pronouncements that we have yet to adopt that are expected to have a material effect on our financial position, results of operations, or cash flows.

**Results of Operations for the Three Months Ended March 31, 2012 as Compared to the Three Months Ended March 31, 2011.**

The following is a comparison of the consolidated results of operations for Tiger X for the three months ended March 31, 2012 and 2011. As discussed above, our Reconstructive Division and Spine Division were discontinued during 2011.

|  | Three Months Ended March 31, 2012 | 2011 | $ Change |
| --- | ---: | ---: | ---: |
| Revenue | $11 | $- | $11 |
| Cost of revenue | - | - | - |
| Gross profit | 11 | - | 11 |
| General and administrative expenses | 69 | 101 | (32) |
| Loss from operations | (58) | (101) | 43 |
| Interest (expense) income, net | 3 | (24) | 27 |
| Loss from continuing operations before income tax provision | (55) | (125) | 70 |
| Provision for income taxes | - | - | - |
| Loss from continuing operations | (55) | (125) | 70 |
| Discontinued operations (Note 1) |  |  |  |
| Loss from operations of discontinued Reconstructive and Spine Divisions, net of income taxes | - | (196) | 196 |
| Net loss | $(55) | $(321) | $266 |

### Revenues

Revenues from continuing operations amounted to $11,000 for the quarter ended March 31, 2012 compared with $0 for the same period in 2011. Revenues from continuing operations represented royalties received from Arthrex in connection with the Arthrex Asset Purchase Agreement. In the future, we expect our primary source of revenue to be royalty payments under the Arthrex Asset Purchase Agreement.

### General and Administrative Expenses

General and administrative expenses for the quarter ended March 31, 2012 decreased by $32,000 as compared to the same period in 2011. General and administrative expenses represent our continuing operating expenses associated with remaining a public company, including business insurance expense and professional fees such as legal, accounting and audit services. The primary reason for the decrease in 2012 relates to higher legal and professional fees incurred in 2011 relating to the sale of our Reconstruction and Spine Divisions. In the future, we expect our general and administrative expenses to remain at a reduced level.

### Interest Income/(Expense)

During the quarter ended March 31, 2011, we had net interest expense of $24,000, which was primarily the result of $500,000 in notes payable outstanding as of December 31, 2010 which were repaid in March 2011. During the quarter ended March 31, 2012, we had interest income of $3,000. We had no interest expense in 2012, as there was no debt outstanding during this timeframe.

### Liquidity and Capital Resources

Net cash used in operating activities was $26,000 for the three months ended March 31, 2012 compared to $558,000 for the same period in 2011. Our overall operating costs were lower in 2012 due to our operations being discontinued and the sales of our Reconstructive and Spine Divisions being finalized in 2011.

Net cash used in investing activities was $0 for the three months ended March 31, 2012 compared to $52,000 for the same period in 2011. During 2011, we purchased $52,000 worth of property and equipment, primarily representing additional instrumentation for our Reconstructive Division prior to the sale being finalized during the second quarter of 2011. During 2012, we did not spend any money on capital expenditures.

Net cash provided by financing activities was $0 for the three months ended March 31, 2012 compared to $724,000 for the three months ended March 31, 2011. The net cash provided by financing activities during 2011 consisted of $1,224,000 in short term borrowings, offset by the repayment of $500,000 in previously outstanding notes payable. The remaining debt was repaid during the second quarter in 2011. There was no cash provided by or used in financing activities during the three months ended March 31, 2012, as we have no further debt outstanding.

We believe our cash and cash equivalents as of March 31, 2012 are adequate to meet our cash needs for the next rwelve months and beyond.

### Forward-Looking Statements

Some of the statements in this Quarterly Report on Form 10-Q are "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "may," "will," "should," "anticipate," "estimate," "expect," "plan," "believe," "predict," "potential," "project," "target," "forecast," "intend," "assume," "guide," "seek" and similar expressions. Forward-looking statements do not relate strictly to historical or current matters. Rather, forward-looking statements are predictive in nature and may depend upon or refer to future events, activities or conditions. Although we believe that these statements are based upon reasonable assumptions, we cannot provide any assurances regarding future results. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. Information regarding our risk factors appears in Part I, Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2011 filed on March 29, 2012.

## Controls and procedures

As filed, 1,977 characters.

#### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our interim principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

We carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and interim principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2012.

The determination that our disclosure controls and procedures were not effective as of March 31, 2012 are a result of:

the departure of the former Chief Financial Officer in late June 2011;

the fact that we no longer have significant operations and as a result have eliminated our internal accounting and financial department; and

insufficient segregation of duties.

#### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed May 15, 2012.
Source: SEC EDGAR, the filing index for accession 0001136261-12-000295. Last ingested by Listed: Nov 13, 2026, 15:46 ET. No prices; not investment advice.
